Peptide Therapeutics Market : Key Players, Challenges, and Growth Opportunities

The peptide therapeutics market was valued at $33.3 billion in 2021, and is estimated to reach $64.3 billion by 2031, growing at a CAGR of 6.8% from 2022 to 2031.

Therapeutic peptides constitute a distinct category of pharmaceutical drugs, characterized by a structured sequence of amino acids with a molecular weight typically ranging from 500 to 5000 Da. These approved peptide drugs are designed to address diverse clinical conditions such as diabetes, gastric and metabolic disorders, as well as hormonal imbalances.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭- https://www.alliedmarketresearch.com/request-sample/11591

The primary catalysts propelling this market forward include a growing elderly population and a surge in chronic disease cases. Peptide therapeutics play a crucial role in the treatment of various conditions such as metabolic, oncological, gastrointestinal, neurological, and cardiovascular diseases. According to the Center for Disease Control and Prevention, cardiovascular disease remains a significant concern, with one person succumbing to it every 34 seconds in the U.S. In 2020 alone, approximately 697,000 individuals in the United States died from heart disease, accounting for 1 in every 5 deaths. Consequently, the increasing prevalence of cardiovascular diseases globally, coupled with a rise in the aging population, contributes substantially to the market's expansion.

𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐂𝐎𝐕𝐈𝐃-19

The COVID-19 epidemic is predicted to have a moderately positive impact on the growth of the global peptide therapeutics industry. Many peptide drugs were under clinical trials for the COVID_19 treatment. Furthermore, it is anticipated that the strong government support for the use of peptides in the creation of the COVID-19 vaccine would create a variety of chances for peptide adoption, ultimately accelerating the expansion of the market for peptide treatments. As of May 2020, 15 synthetic peptides were being used to treat ARDS and other respiratory conditions brought on by the SARS-Cov-2 virus, bringing the total number of peptide drugs available for the treatment of COVID-19 to 21.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (369 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬) @ https://www.alliedmarketresearch.com/peptide-therapeutics-market/purchase-options

In 2021, North America held the largest share in the global peptide therapeutics market, a trend expected to persist throughout the forecast period. This dominance is ascribed to advancements in peptide therapeutics development techniques, an increase in cardiovascular diseases, and the presence of robust hospital infrastructure. Nevertheless, the Asia-Pacific region is poised for significant growth due to a rising geriatric population, ongoing healthcare infrastructure development, and increased investment projects in the area.

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the peptide therapeutics market analysis from 2021 to 2031 to identify the prevailing peptide therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the peptide therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global peptide therapeutics market trends, key players, market segments, application areas, and market growth strategies.

𝐃𝐨 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 𝐛𝐞𝐟𝐨𝐫𝐞 𝐛𝐮𝐲𝐢𝐧𝐠 - https://www.alliedmarketresearch.com/purchase-enquiry/11591

𝑲𝒆𝒚 𝒇𝒊𝒏𝒅𝒊𝒏𝒈𝒔 𝒐𝒇 𝒕𝒉𝒆 𝒔𝒕𝒖𝒅𝒚
• By application, the metabolic segment was the highest contributor to the peptide therapeutics industry in 2021.
• By route of administration, the parenteral segment was the highest contributor to the peptide therapeutics industry in 2021.
• Depending on distribution channel, the hospital pharmacies segment was highest contributor in 2021, and is expected to continue this trend during the forecast period.
• Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 -
• Eli Lilly and Company
• Amgen Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Novo Nordisk A/S
• Sanofi SA
• Ever Neuro Pharma GmbH
• Bausch Health
• GlaxoSmithKline plc
• Abbvie (Allergan)

𝑲𝒏𝒐𝒘 𝑴𝒐𝒓𝒆- https://www.alliedmarketresearch.com/peptide-therapeutics-market-A11226

𝑶𝒕𝒉𝒆𝒓 𝑻𝒓𝒆𝒏𝒅𝒊𝒏𝒈 𝑹𝒆𝒑𝒐𝒓𝒕𝒔 𝒊𝒏 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆 𝑫𝒐𝒎𝒂𝒊𝒏
𝑩𝒐𝒕𝒖𝒍𝒊𝒏𝒖𝒎 𝑻𝒐𝒙𝒊𝒏 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/botulinum-toxin-market-A11935

𝑮𝒍𝒐𝒗𝒆𝒔 𝒎𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/gloves-market-A08867

𝑴𝒆𝒅𝒊𝒄𝒂𝒍 𝑪𝒐𝒐𝒍𝒊𝒏𝒈 𝑺𝒚𝒔𝒕𝒆𝒎 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/medical-cooling-system-market

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com

Alied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.